What are the therapeutic indications for doxepin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Doxepin Used For?

Doxepin is FDA-approved for treating depression and anxiety disorders at doses of 10–300 mg daily, and at low doses (3–6 mg) it is specifically recommended by the American Academy of Sleep Medicine for sleep-maintenance insomnia. 1, 2

FDA-Approved Indications (Standard Antidepressant Doses: 10–300 mg/day)

Doxepin hydrochloride capsules are FDA-approved for the following conditions 1:

  • Psychoneurotic patients with depression and/or anxiety – Target symptoms include anxiety, tension, depression, somatic concerns, sleep disturbances, guilt, lack of energy, fear, apprehension, and worry 1
  • Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol) 1
  • Depression and/or anxiety associated with organic disease (drug interactions must be considered if the patient is receiving other medications) 1
  • Psychotic depressive disorders with associated anxiety, including involutional depression and manic-depressive disorders 1

At these antidepressant doses, doxepin works by preventing the reuptake of norepinephrine at nerve terminals, though its exact mechanism is not definitively known 1. It is not a CNS stimulant or monoamine oxidase inhibitor 1.

Guideline-Recommended Use: Low-Dose Doxepin (3–6 mg) for Sleep-Maintenance Insomnia

The American Academy of Sleep Medicine recommends doxepin 3–6 mg as a treatment for sleep-maintenance insomnia in adults (weak recommendation based on low-quality evidence). 2

Evidence of Efficacy

  • Meta-analysis shows that doxepin 3–6 mg produces clinically significant improvements in:

    • Wake after sleep onset (WASO) – reduced by 22–23 minutes 2
    • Total sleep time (TST) – increased by 28–57 minutes 2
    • Sleep efficiency (SE) – objective SE exceeded clinical significance thresholds at both 3 mg and 6 mg doses 2
    • Sleep quality – moderate improvement at 3 mg, mild improvement at 6 mg 2

  • Polysomnography (PSG) and patient-reported outcomes both demonstrate benefit, though PSG data for WASO at 6 mg fell slightly below threshold in some studies 2

  • Sleep-onset latency (SL) improvements were minimal – PSG and subjective SL at 3 mg and PSG SL at 6 mg fell below clinical significance thresholds, indicating doxepin is not ideal for sleep-onset insomnia 2

Safety Profile at Low Doses

  • Side effects at 3–6 mg are comparable to placebo, with limited adverse events reported 2
  • Common side effects include headache, diarrhea, somnolence, and upper respiratory infection at 3 mg; headache and somnolence at 6 mg 2
  • Mild increase in somnolence at 6 mg was the only notable adverse effect 2
  • At hypnotic doses (3–6 mg), doxepin has minimal anticholinergic activity – unlike higher antidepressant doses, low-dose doxepin does not cause significant dry mouth, urinary retention, or cognitive impairment 2
  • No abuse potential or dependence risk at low doses 2, 3

Clinical Trials Supporting Low-Dose Use

  • Krystal et al. (12-week RCT) – 240 elderly patients (>65 years) with sleep-maintenance insomnia; doxepin 1 mg and 3 mg vs. placebo; both PSG and sleep diary data showed efficacy 2
  • Krystal et al. (5-week trial) – 221 adults with sleep-onset and maintenance insomnia; doxepin 3 mg and 6 mg vs. placebo; PSG and sleep diaries demonstrated benefit 2
  • Roth et al. (crossover design) – 67 adults with sleep-onset and maintenance insomnia; doxepin 1 mg, 3 mg, 6 mg vs. placebo; PSG and sleep diary data collected 2
  • Scharf et al. (crossover design) – 76 elderly insomnia patients; identical design to Roth study 2
  • Lankford et al. (4-week trial) – 254 elderly patients; doxepin 6 mg vs. placebo; patient-reported and clinician-rated outcomes 2

Off-Label Uses (Supported by Research but Not FDA-Approved)

1. Chronic Pain with Comorbid Depression

  • A 6-week randomized, double-blind, placebo-controlled trial in 60 patients with chronic low back or cervical spine pain and clinical depression showed:
    • Significant improvements in Hamilton depression scores, Global Assessment Scale scores, pain severity, percent of time pain felt, and effect of pain on activity, sleep, and muscle tension 4
    • Most improvement occurred at 6 weeks with a mean doxepin dose of approximately 200 mg/day (plasma doxepin and nordoxepin averaged 80 ng/ml) 4
    • Some improvements were observed after 1 week of treatment 4
    • No significant harmful effects were observed 4
    • Neither plasma beta-endorphin nor enkephalin-like activity showed significant changes, suggesting the mechanism is not opioid-mediated 4

2. Chronic Depression (Long-Term Maintenance)

  • A 15-year prospective study of long-term doxepin use (5–15 years) in chronic depression patients demonstrated:
    • Doxepin is feasible, efficacious, and safe for long-term maintenance treatment 5
    • Lack of adverse interactions with prescription and non-prescription drugs 5
    • High degree of safety in patients with concomitant cardiovascular and other physical disorders 5
    • Doxepin appears to be an excellent choice for long-term outpatient treatment of chronic depression 5

3. Generalized Pruritus (Topical Use)

  • The British Association of Dermatologists recommends topical doxepin for generalized pruritus of unknown origin (GPUO), but with strict limitations 2:
    • Treatment should be limited to 8 days, 10% of body surface area, and a maximum of 12 g daily (Strength of recommendation D; Level of evidence 4) 2
    • Risk of allergic contact dermatitis is a concern with topical doxepin 2
    • A meta-analysis of 19 RCTs suggested topical doxepin has a role in managing generalized pruritus, but evidence for other topical antihistamines was lacking 2

Mechanism of Action

At Antidepressant Doses (10–300 mg/day)

  • Prevents reuptake of norepinephrine at nerve terminals, increasing adrenergic activity at synapses 1
  • Anticholinergic, antiserotonin, and antihistamine effects on smooth muscle (demonstrated in animal studies) 1
  • At higher doses, norepinephrine response is potentiated in animals (not demonstrated in humans) 1
  • Does not appreciably antagonize the antihypertensive action of guanethidine at doses up to 150 mg/day 1
  • At doses above 150 mg/day, blocking of the antihypertensive effect of guanethidine has been reported 1

At Low Hypnotic Doses (3–6 mg)

  • Selective H1-histamine receptor antagonism is the primary mechanism 2, 6
  • Minimal anticholinergic and antinoradrenergic activity at low doses, avoiding dose-limiting side effects seen at higher doses 6
  • Preferential effects on sleep maintenance (rather than sleep initiation) due to histamine's role in the sleep-wake cycle 6

Contraindications and Precautions

Absolute Contraindications

  • Hypersensitivity to doxepin or other dibenzoxepines 1
  • Glaucoma or tendency to urinary retention (especially in older patients) 1

Black Box Warning: Suicidality Risk

  • Antidepressants, including doxepin, increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18–24) with major depressive disorder (MDD) and other psychiatric disorders 1
  • Short-term studies did not show an increase in suicidality risk in adults beyond age 24; there was a reduction in risk in adults aged 65 and older 1
  • All patients starting antidepressant therapy should be monitored closely for clinical worsening, suicidality, or unusual changes in behavior, especially during the initial few months of treatment or at times of dose changes 1
  • Families and caregivers should be advised to monitor for emergence of agitation, irritability, unusual behavior changes, and suicidality, and to report such symptoms immediately 1

Special Populations

  • Pediatric use: Doxepin is not recommended for children under 12 years of age due to lack of clinical experience 1
  • Geriatric use: Doxepin is safe and well-tolerated in elderly patients, but once-daily dosing should be adjusted carefully based on the patient's condition 1
  • Pregnancy: Reproduction studies in animals showed no evidence of harm, but safety in pregnant women has not been established 1
  • Nursing mothers: A report of apnea and drowsiness in a nursing infant whose mother was taking doxepin has been documented 1

Common Pitfalls and Caveats

  • Do not use doxepin for sleep-onset insomnia – it is specifically effective for sleep-maintenance problems, not for difficulty falling asleep 2
  • Do not exceed 20 mg/day for insomnia – higher doses increase anticholinergic burden without additional sleep benefit 2, 3
  • Do not use topical doxepin for more than 8 days or on more than 10% of body surface area – risk of allergic contact dermatitis and systemic absorption 2
  • Do not abruptly discontinue doxepin after long-term use – taper gradually to avoid withdrawal symptoms 5
  • Screen for bipolar disorder before initiating doxepin – treating a depressive episode with an antidepressant alone may precipitate a manic episode in patients at risk for bipolar disorder 1
  • Monitor for angle-closure glaucoma – pupillary dilation from doxepin may trigger an angle-closure attack in patients with anatomically narrow angles 1

Summary

Doxepin is a versatile tricyclic agent with FDA approval for depression and anxiety at standard doses (10–300 mg/day) and guideline-recommended use at low doses (3–6 mg) for sleep-maintenance insomnia. 2, 1 It has a favorable safety profile at low doses, with minimal anticholinergic effects and no abuse potential, making it particularly suitable for elderly patients with chronic insomnia. 2 Off-label uses include chronic pain with depression and long-term maintenance treatment of chronic depression, supported by robust clinical trial data. 4, 5 However, it carries a black box warning for suicidality risk in younger patients and should be used with caution in specific populations. 1

References

2
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

3
Guideline

Pharmacotherapy of Insomnia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Research

Doxepin's effects on chronic pain and depression: a controlled study.

The Journal of clinical psychiatry, 1984

6
Research

Low-dose doxepin for the treatment of insomnia: emerging data.

Expert opinion on pharmacotherapy, 2009

Related Questions

What is the comparison between doxepin (Silenor) and trazodone (Oleptro) for treating insomnia in adult patients, particularly those with sleep maintenance issues and potential risks in elderly patients over 65?
What is the next best step in evaluating a healthy 13-year-old with absent puberty, bone age of 11.5 years, and height 157 cm?
In a 19‑year‑old female with a three‑month history of progressive right‑temporal headache aggravated by coughing, cold exposure, bright light, and fan airflow, now accompanied by right‑sided painful ophthalmoplegia (intermittent diplopia that resolves when one eye is covered, medial deviation of the right eye, right upper‑eyelid ptosis, and retro‑orbital pain) and no fever or other systemic signs, what is the most likely diagnosis and what urgent investigations and initial management are recommended?
What is the appropriate evaluation and initial management for a 19‑year‑old male with severe unexplained weight loss?
How should I evaluate and manage a patient with a blood pressure of 122/77 mm Hg and a heart rate of 123 beats per minute (tachycardia)?
Should lamivudine 100 mg be continued at its standard dose during chemotherapy, and do renal function changes require dose adjustment?
What is the recommended starting dose and titration schedule for a fentanyl infusion for analgesia in an adult postoperative or ICU patient?
What is the recommended management for a neonate presenting with a distended abdomen?
Can you outline the step‑by‑step procedure for coronary angiography and percutaneous coronary intervention (angioplasty)?
What is the incidence of bronchospasm associated with nebulized N‑acetylcysteine (Fluimucil)?
When should an insulin infusion be started in an adult critically ill patient with uncontrolled hyperglycemia (e.g., blood glucose ≥250 mg/dL with ketosis or ≥300 mg/dL in hyperosmolar hyperglycemic state)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question